HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor.
The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications and device hardware.
HeartBeam’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. For more information, view the full press release at https://ibn.fm/jgVf0 and the latest news at https://ibn.fm/BEAT.
